Immatics

+$0.07 (+1.10%) As of 11:59 AM UTC pre-market

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Immatics and other ETFs, options, and stocks.

About IMTX

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline include adoptive cell therapy and TCR Bispecifics.The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany.

CEO
Harpreet Singh-Jasuja
Employees
255
Headquarters
Tuebingen, Baden Wuerttemberg
Founded
2000

IMTX Key Statistics

Market cap
399.59M
Price-Earnings ratio
—
Dividend yield
—
Average volume
213.73K
High today
$6.64
Low today
$6.31
Open price
$6.45
Volume
99.70K
52 Week high
$16.30
52 Week low
$5.75

IMTX Earnings

-$0.54
-$0.36
-$0.18
$0.00
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Estimated
— per share
Actual
Expected May 31, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure